Infinitopes, a clinical-stage biotech developing precision cancer vaccines, has completed a second close of its seed financing, raising an additional $15.4 million to bring the total round to $35.1 million. The round was co-led by Octopus Ventures and new investor Amplify Bio, with Macmillan Cancer Support joining alongside existing investors Cancer Research Horizons and Manta Ray Ventures.

The funding will support Infinitopes’ first-in-human clinical trial of ITOP1, a precision therapeutic vaccine designed to prevent recurrence in oesophageal cancer, a disease area with significant unmet medical need. The Phase 1/2a VISTA trial will be conducted across multiple UK NHS university cancer centres and will assess the AI-driven, off-the-shelf vaccine platform’s proof-of-concept efficacy and safety.

Jonathan Kwok, chief executive officer of Infinitopes, said: “I’m honoured to welcome Amplify Bio and Macmillan Cancer Support onto our cap table. This new funding unlocks our Phase I/IIa trial, enabling evaluation of Infinitopes’ AI/ML-guided precision vaccine platform to prevent recurrence after surgical resection. We aim to develop innovative medicines that bring hope to patients with cancers where treatment options are limited, and we anticipate sharing early findings at major conferences later this year.”

Elliot Hershberg, partner at Amplify Bio, added: “Recent clinical evidence shows the time for cancer vaccines is now. Infinitopes stands out with its AI-powered immunomics profiling, scalable off-the-shelf vector, and clear clinical strategy. The company has the potential to redefine immunotherapy and precision oncology in the years ahead.”

The new funding positions Infinitopes to accelerate clinical development of ITOP1 and further strengthen its platform for precision cancer vaccines targeting diseases with high unmet need.